BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Array BioPharma, Inc. (ARRY) to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts


11/1/2012 11:03:01 AM

BOULDER, Colo., Nov. 1, 2012 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will hold a conference call on Monday, November 5, 2012 at 4:30 p.m. Eastern Time to discuss submitted 2012 American Society of Hematology Annual Meeting abstracts on ARRY-520, a KSP inhibitor for multiple myeloma and ARRY-614, a dual p38/Tie2 inhibitor for myelodysplasticsyndromes. Ron Squarer, Chief Executive Officer and Kevin Koch, Ph.D., President and Chief Scientific Officer, will lead the call.

Conference Call Information

Date:

Monday, November 5, 2012

Time:

4:30 p.m. Eastern Time

Toll-Free:

(888) 895-5479

Toll:

(847) 619-6250

Pass Code:

33684333

Webcast & Conference Call Slides: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome

A replay of the call will be available as a webcast on www.arraybiopharma.com

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted smallmolecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two whollyowned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune / Roche), having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013. For more information on Array, please go to www.arraybiopharma.com.

SOURCE Array BioPharma Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES